Acorda data support 2013 NDA for intranasal diazepam
This article was originally published in Scrip
Executive Summary
Acorda Therapeutics revealed data on 20 March from one of the three studies that will support its new drug application (NDA) to the US FDA this year for an intranasal formulation of diazepam to control acute seizures at the 65th Annual American Academy of Neurology (AAN) Annual Meeting in San Diego.